"Assessing the Health Risks and Perceptions of New Weight Loss Drugs in America"
The rise of new weight loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound presents both opportunities and risks, as patients must use these drugs in combination with diet and exercise programs. Companies like WeightWatchers and Noom are entering the clinicals business to provide guidance for patients prescribed these drugs, but concerns remain about overreliance on medication and the need for lifestyle-based programs. With the cost of these drugs and uncertainties about long-term effects, the industry is navigating the challenge of balancing risks and benefits while seeking to capture a sizable piece of the market.